DiaMedica Therapeutics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $430.9M
- Price
- $7.99
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.72%
- Volume
- 221.2K
About
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
Quick stats
Shares outstanding53.9M
Computed float24.3M
Float / shares45.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001401040
Websitehttps://www.diamedica.com
AI Summary
AI-generated1/17
minorbullishclinical trial
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results
DiaMedica Therapeutics will host a virtual KOL webinar on October 23, 2026 to discuss DM199 (rinvecalinase alfa) as a potential treatment for fetal growth restriction.
The event will feature preliminary, interim topline results from the first cohort of six participants dosed at 5 µg/kg in an investigator-sponsored Phase 2 early-onset FGR trial at Tygerberg Hospital, South Africa.
First cohort enrollment is complete and dosing has begun in the second cohort at 10 µg/kg; the trial plans up to 30 subjects across three dose levels.
Interim data is from a very small sample in an open-label, single-arm study, so findings are early signals rather than definitive results.
Red flags
- interim results based on only six participants; preliminary and not indicative of final trial outcomes